# Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer

> **NCT00388960** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 99 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Amrubicin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00388960
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-01
- **Primary completion:** 2010-04-01
- **Final completion:** 2010-12-01
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388960, "Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00388960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*